CDXS

In the past six months, Codexis, Inc. (CDXS) stock experienced a 44.40% decline, from $2.50 per share on October 1, 2025, to $1.39 on September 30, 2026. Over the last 12 months, the stock's price decreased by 43.03%, with a year-to-date return of -14.72%. In the past month leading up to September 30, 2026, the stock decreased by 12.58%. Key events impacting the stock include the Q4 2025 earnings release on March 11, 2026, with an actual EPS of $0.110. The Q1 2026 earnings release on May 7, 2026, reported an actual EPS of -$0.100. The Annual General Meeting was held on June 17, 2026. In July 2026, Codexis completed an equity capital raise of approximately $25 million in net proceeds, strengthening its balance sheet. The Q2 2026 earnings, announced on August 11, 2026, reported an EPS of -$0.13 and quarterly revenue of $14.92 million, both beating analysts' consensus estimates. The company participated in the Cantor Global Healthcare Conference on September 10, 2026. On September 28, 2026, Codexis announced an agreement with a pioneering siRNA drug innovator to leverage its ECO Synthesis Manufacturing Platform to create stereo-defined siRNA.